Beam Therapeutics Inc.

NasdaqGS:BEAM 주식 보고서

시가총액: US$1.9b

Beam Therapeutics 배당금 및 환매

배당금 기준 확인 0/6

Beam Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-2.1%

환매 수익률

총 주주 수익률-2.1%
미래 배당 수익률0%
배당금 성장n/a
다음 배당금 지급일n/a
전 배당일n/a
주당 배당금n/a
지급 비율n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 07

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

Sep 29

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Slow Developmental Progress, But Promising Potential

Jul 01

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

Nov 01
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Apr 08
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Beam Therapeutics: Now Is Not The Right Time To Own

Sep 15

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Aug 09

Beam drops 19% as FDA issues clinical hold on blood cancer candidate

Aug 01

Revisiting Beam Therapeutics Among Collaborative Catalysts

Jul 10

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Apr 21

Beam Therapeutics: Getting More And More Interesting

Apr 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

Jan 19

Beam Therapeutics: An Early Company In A Promising Field

Dec 27

Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

Dec 20

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

Oct 01

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 BEAM 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: BEAM 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.


시장 대비 배당 수익률

Beam Therapeutics 시장 대비 배당 수익률
BEAM 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트배당 수익률
회사 (BEAM)n/a
시장 하위 25% (US)1.4%
시장 상위 25% (US)4.3%
업계 평균 (Biotechs)2.3%
애널리스트 예측 (BEAM) (최대 3년)0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BEAM 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BEAM 의 배당 수익률을 평가할 수 없습니다.


주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BEAM 의 지급 비율을 계산하기에는 데이터가 부족합니다.


주주에 대한 현금 배당금

현금 흐름 범위: BEAM 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.


강력한 배당금 지급 기업 알아보기